Suppliers and packagers for generic pharmaceutical drug: EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Septodont Inc	PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE	epinephrine bitartrate; prilocaine hydrochloride	INJECTABLE;INJECTION	078959	ANDA	Dentsply Pharmaceutical Inc.	66312-580-16	50 CARTRIDGE in 1 CARTON (66312-580-16) / 1.8 mL in 1 CARTRIDGE	2017-12-04

Epinephrine Bitartrate and Prilocaine Hydrochloride: Key Supplier Landscape and Patent Analysis

Last updated: February 19, 2026

This report analyzes the supplier landscape and patent situation for Epinephrine Bitartrate and Prilocaine Hydrochloride, essential components in local anesthetic formulations. Key findings indicate a concentrated supplier base for both active pharmaceutical ingredients (APIs), with limited recent patent filings suggesting a mature market. Market participants must navigate existing intellectual property and secure reliable API sources.

Who are the Primary Suppliers of Epinephrine Bitartrate?

The global supply of Epinephrine Bitartrate is concentrated among a limited number of manufacturers. These suppliers are critical for pharmaceutical companies developing and manufacturing anesthetic products.

• Major Suppliers:
  • Fresenius Kabi Deutschland GmbH: A significant player in the pharmaceutical manufacturing sector, known for its sterile injectable products.
  • Akorn India Private Limited: Part of the broader Akorn, Inc. network, this entity contributes to API production.
  • Piramal Pharma Solutions: A contract development and manufacturing organization (CDMO) with a global presence, offering API manufacturing services.
  • Evolan Pharma AB: A Swedish pharmaceutical company that sources and supplies APIs for various formulations.

These suppliers are often subject to stringent regulatory oversight, including inspections by bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Facility audits and quality control are paramount for ensuring API purity and compliance.

What is the Patent Status for Epinephrine Bitartrate?

The patent landscape for Epinephrine Bitartrate itself is largely characterized by expired foundational patents. The molecule's discovery and initial patent protection occurred decades ago. Current patent activity primarily focuses on novel formulations, delivery systems, and manufacturing processes rather than the API's core structure.

• Patent Expiry: Original composition of matter patents for Epinephrine Bitartrate have long expired, allowing for generic production.
• Focus of Recent Filings:
  • Improved Stability Formulations: Patents may cover specific excipient combinations or pH adjustments that enhance the shelf-life of Epinephrine Bitartrate solutions, particularly in light of its known instability.
  • Novel Delivery Devices: Innovations in auto-injectors, pre-filled syringes, or metered-dose inhalers incorporating Epinephrine Bitartrate are areas of active patenting.
  • Manufacturing Process Improvements: Patents might protect novel synthetic routes or purification methods that increase yield, reduce impurities, or lower production costs.

A comprehensive review of patent databases, such as those maintained by the United States Patent and Trademark Office (USPTO) and the European Patent Office (EPO), is necessary to identify specific, active patents relevant to a particular product or process. For instance, searches for "epinephrine stability formulation" or "epinephrine auto-injector" reveal ongoing innovation.

Which Companies Hold Patents Related to Epinephrine Bitartrate Formulations or Manufacturing?

While the core API is off-patent, specific companies have secured intellectual property around its application and production.

• Companies with Relevant Patent Filings (Examples):
  • Mylan N.V. (now Viatris Inc.): Has filed patents related to the stabilization and delivery of epinephrine formulations.
  • Teva Pharmaceutical Industries Ltd.: Has a history of patenting in the generic drug space, including potential process improvements.
  • Indivior PLC: While known for addiction treatment, their patent portfolio may include broad claims that could encompass stabilization technologies applicable to various injectables.

These companies' patent activities signal areas of commercial interest, such as extending product exclusivity through formulation patents or defending market share with process innovations.

Who are the Primary Suppliers of Prilocaine Hydrochloride?

Similar to Epinephrine Bitartrate, the manufacturing of Prilocaine Hydrochloride API is concentrated. This concentration underscores the importance of supplier relationships and supply chain security.

• Major Suppliers:
  • Teva Pharmaceutical Industries Ltd.: A global leader in generic pharmaceuticals, Teva is a significant producer of various APIs, including Prilocaine Hydrochloride.
  • Alkem Laboratories Ltd.: An Indian pharmaceutical company with a substantial API manufacturing base.
  • Sun Pharmaceutical Industries Ltd.: Another major Indian pharmaceutical firm with extensive API production capabilities.
  • Accord Healthcare Ltd.: Part of the Intas Pharmaceuticals group, Accord is involved in manufacturing and supplying APIs globally.

The sourcing of Prilocaine Hydrochloride requires rigorous qualification of suppliers to ensure Good Manufacturing Practice (GMP) compliance and consistent product quality, meeting pharmacopeial standards such as those set by the United States Pharmacopeia (USP) or European Pharmacopoeia (EP).

What is the Patent Status for Prilocaine Hydrochloride?

Prilocaine Hydrochloride, like Epinephrine Bitartrate, has foundational patents that have expired. Its development dates back to the mid-20th century. Current patent filings primarily target advancements in its application and production methods.

• Patent Expiry: The original patents covering the Prilocaine molecule are no longer in force.
• Areas of Ongoing Patent Activity:
  • Combination Therapies: Patents may cover novel combinations of Prilocaine Hydrochloride with other active ingredients, such as epinephrine, for synergistic anesthetic effects or to mitigate side effects.
  • Topical Formulations: Innovations in creams, gels, or patches designed for transdermal delivery of Prilocaine Hydrochloride for procedures like venipuncture or minor dermatological surgery.
  • Controlled-Release Mechanisms: Development of formulations that provide prolonged anesthetic action, reducing the need for frequent administration.
  • Manufacturing Process Patents: Refinements in synthesis or purification that enhance efficiency, reduce environmental impact, or improve the impurity profile of the API.

Analysis of patent databases for terms like "prilocaine topical," "prilocaine controlled release," or "prilocaine manufacturing process" can reveal specific innovative claims.

Which Companies Hold Patents Related to Prilocaine Hydrochloride Formulations or Manufacturing?

Several pharmaceutical companies have actively patented innovations surrounding Prilocaine Hydrochloride.

• Companies with Relevant Patent Filings (Examples):
  • Allergan, Inc. (now part of AbbVie Inc.): Has historically held patents related to topical anesthetic formulations, including those containing prilocaine.
  • Novartis AG: Their broad patent portfolio may include innovations in anesthetic delivery systems or combination products.
  • Sanofi S.A.: A major pharmaceutical player with interests in anesthetics and injectable products, potentially holding patents on formulation improvements.

These patents indicate strategic directions for market differentiation and potential for new product development or licensing opportunities.

What are the Key Considerations for Sourcing These APIs?

Securing a reliable and compliant supply of Epinephrine Bitartrate and Prilocaine Hydrochloride requires careful consideration of several factors.

• Regulatory Compliance: Suppliers must adhere to cGMP standards. Audits of manufacturing facilities and review of Drug Master Files (DMFs) are essential.
• Quality Assurance: Consistent API purity, absence of critical impurities, and compliance with pharmacopeial monographs (e.g., USP, EP) are non-negotiable.
• Supply Chain Stability: Evaluating supplier's production capacity, geopolitical risks, and historical reliability is crucial to mitigate supply chain disruptions. Dual sourcing strategies may be advisable.
• Cost and Commercial Terms: Negotiating competitive pricing while ensuring long-term supply agreements.
• Intellectual Property Landscape: Understanding existing patents related to formulations, delivery systems, or manufacturing processes is vital to avoid infringement and identify potential licensing or collaborative opportunities.

What are the Growth Drivers and Challenges for these APIs?

The market for Epinephrine Bitartrate and Prilocaine Hydrochloride is influenced by several factors.

• Growth Drivers:
  • Increasing Demand for Local Anesthetics: Driven by a growing elderly population requiring surgical procedures, advancements in dental treatments, and an increase in minimally invasive medical interventions.
  • Emergency Medical Preparedness: Epinephrine's critical role in treating anaphylaxis ensures continued demand.
  • Innovation in Delivery Systems: Development of more convenient and user-friendly devices can expand market applications.
• Challenges:
  • API Price Volatility: Fluctuations in raw material costs and manufacturing complexities can impact pricing.
  • Regulatory Scrutiny: Increasingly stringent quality and manufacturing standards can increase compliance costs for suppliers.
  • Competition from Alternative Anesthetics: Development of newer anesthetic agents with improved profiles or different mechanisms of action.
  • Epinephrine Stability Issues: The inherent instability of epinephrine solutions necessitates specialized handling and formulation expertise, presenting a continuous development challenge.

Key Takeaways

The supply chains for Epinephrine Bitartrate and Prilocaine Hydrochloride are dominated by a few key global API manufacturers. Both APIs have foundational patents that have expired, shifting the focus of recent intellectual property to novel formulations, delivery systems, and manufacturing processes. Pharmaceutical companies must prioritize regulatory compliance, robust quality assurance, and supply chain security when sourcing these critical ingredients. Navigating the patent landscape is essential to avoid infringement and identify opportunities for product differentiation.

FAQs

1. Are there any active composition-of-matter patents for Epinephrine Bitartrate or Prilocaine Hydrochloride? No, the original patents covering the core chemical structures of both Epinephrine Bitartrate and Prilocaine Hydrochloride have expired. Current patent activity relates to specific applications and manufacturing methods.

2. What regulatory bodies oversee the manufacturing of these APIs? Major regulatory bodies include the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and national agencies within other key markets. Compliance with Good Manufacturing Practices (GMP) is mandatory.

3. How can a company ensure the quality and consistency of API from its chosen suppliers? This involves conducting thorough supplier audits, reviewing Drug Master Files (DMFs), verifying compliance with pharmacopeial standards (e.g., USP, EP), and establishing rigorous incoming quality control testing.

4. What is the primary risk associated with the Epinephrine Bitartrate supply chain? A significant risk is the inherent instability of epinephrine, which requires specialized formulation and storage, impacting shelf-life and manufacturing complexity. Supply chain disruptions from a limited supplier base also pose a risk.

5. Are there opportunities for new patent filings in the anesthetic space related to these APIs? Yes, opportunities exist in developing novel combination therapies, advanced drug delivery devices (e.g., improved auto-injectors, transdermal patches), enhanced stability formulations, and more efficient or environmentally friendly manufacturing processes.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from [FDA website address if publicly available and specific] [2] European Medicines Agency. (n.d.). Procedures and guidance. Retrieved from [EMA website address if publicly available and specific] [3] United States Patent and Trademark Office. (n.d.). USPTO Patent Search. Retrieved from [USPTO website address] [4] European Patent Office. (n.d.). Espacenet patent search. Retrieved from [EPO website address] [5] United States Pharmacopeia. (n.d.). USP-NF Online. Retrieved from [USP website address if publicly available and specific] [6] European Pharmacopoeia. (n.d.). Ph. Eur. Online. Retrieved from [EDQM website address if publicly available and specific]